全文获取类型
收费全文 | 811篇 |
免费 | 35篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 39篇 |
妇产科学 | 3篇 |
基础医学 | 73篇 |
口腔科学 | 10篇 |
临床医学 | 68篇 |
内科学 | 200篇 |
皮肤病学 | 2篇 |
神经病学 | 26篇 |
特种医学 | 320篇 |
外科学 | 19篇 |
综合类 | 15篇 |
预防医学 | 29篇 |
眼科学 | 4篇 |
药学 | 44篇 |
中国医学 | 2篇 |
肿瘤学 | 13篇 |
出版年
2022年 | 2篇 |
2021年 | 11篇 |
2018年 | 8篇 |
2017年 | 2篇 |
2015年 | 8篇 |
2014年 | 7篇 |
2013年 | 11篇 |
2012年 | 9篇 |
2011年 | 7篇 |
2010年 | 18篇 |
2009年 | 20篇 |
2008年 | 11篇 |
2007年 | 24篇 |
2006年 | 11篇 |
2005年 | 10篇 |
2004年 | 8篇 |
2003年 | 7篇 |
2002年 | 9篇 |
2001年 | 7篇 |
2000年 | 7篇 |
1999年 | 13篇 |
1998年 | 47篇 |
1997年 | 40篇 |
1996年 | 57篇 |
1995年 | 43篇 |
1994年 | 33篇 |
1993年 | 38篇 |
1992年 | 9篇 |
1991年 | 13篇 |
1990年 | 15篇 |
1989年 | 34篇 |
1988年 | 37篇 |
1987年 | 30篇 |
1986年 | 27篇 |
1985年 | 40篇 |
1984年 | 22篇 |
1983年 | 23篇 |
1982年 | 28篇 |
1981年 | 24篇 |
1980年 | 12篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 30篇 |
1976年 | 19篇 |
1975年 | 15篇 |
1970年 | 2篇 |
1968年 | 2篇 |
1965年 | 1篇 |
1961年 | 1篇 |
1959年 | 1篇 |
排序方式: 共有868条查询结果,搜索用时 9 毫秒
31.
Marchaim D Chopra T Bogan C Bheemreddy S Sengstock D Jagarlamudi R Malani A Lemanek L Moshos J Lephart PR Ku K Hasan A Lee J Khandker N Blunden C Geffert SF Moody M Hiro R Wang Y Ahmad F Mohammadi T Faruque O Patel D Pogue JM Hayakawa K Dhar S Kaye KS 《American journal of infection control》2012,40(8):760-765
32.
O'Malley CJ; Rasko JE; Basser RL; McGrath KM; Cebon J; Grigg AP; Hopkins W; Cohen B; O'Byrne J; Green MD; Fox RM; Berndt MC; Begley CG 《Blood》1996,88(9):3288-3298
This report describes the effect of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet production and platelet function in humans. Subjects with advanced solid tumors received PEG-rHuMGDF daily for up to 10 days. There was no increase in circulating platelet count at doses of 0.03 or 0.1 microgram/kg/d by day 12 of study. At doses of 0.3 and 1.0 microgram/kg/d there was a threefold median increase (maximum 10-fold) in platelet count by day 16. The platelets produced in vivo in response to PEG-rHuMGDF showed unchanged aggregation and adenosine triphosphate (ATP)-release responses in in vitro assays. Tests included aggregation and release of ATP in response to adenosine diphosphate (ADP) (10, 5, 2.5, and 1.25 mumol/L), collagen (2 micrograms/mL), thrombin-receptor agonist peptide (TRAP, 10 mumol/L) and ristocetin (1.5 mg/mL). Administration of aspirin to an individual with platelet count of 1,771 x 10(3)/L resulted in the typical aspirin-induced ablation of the normal aggregation and ATP-release response to stimulation with arachidonic acid (0.5 mg/mL), collagen, and ADP (2.5 and 1.25 mumol/L). There was no change in the expression of the platelet-surface activation marker CD62P (P-selectin) nor induction of the fibrinogen binding site on glycoprotein IIb/IIIa as reported by the monoclonal antibody, D3GP3. An elevation of reticulated platelets was evident after 3 days of treatment with PEG-rHuMGDF and preceded the increase in circulating platelet count by 5 to 8 days; this reflected the production of new platelets in response to PEG-rHuMGDF. At later time points, the mean platelet volume (MPV) decreased in a manner inversely proportional to the platelet count. Levels of plasma glycocalicin, a measure of platelet turnover, rose 3 days after the initial increase in the peripheral platelet count. The level of plasma glycocalicin was proportional to the total platelet mass, suggesting that platelets generated in response to PEG-rHuMGDF were not more actively destroyed. Thus, the administration of PEG-rHuMGDF, to humans, increased the circulating platelet count and resulted in fully functional platelets, which showed no detectable increase in reactivity nor alteration in activation status. 相似文献
33.
New Zealand Black (NZB) autoimmune mice exhibit progressive, age- dependent reduction in bone marrow pre-B cells. To ascertain the capacity of NZB bone marrow B220- cells to generate pre-B cells in a supportive environment, B-lineage (B220+) cell-depleted and T-cell- depleted bone marrow cells from NZB mice at 1 to 3, 6, and 10 to 11 months of age were adoptively transferred into irradiated (200R) C.B17 severe combined immunodeficient (SCID) mice. Bone marrow pre-B cells (sIgM- CD43[S7]- B220+) were assessed 3 and 10 weeks posttransfer. Pre- B cells and B cells were reconstituted in SCID recipients of older NZB progenitor cells by 10 weeks posttransplant, in contrast to the very low numbers of pre-B cells present in the donor bone marrow. However, B220- bone marrow progenitor cells from greater than 10-month-old NZB donors were deficient in the reconstitution of both pre-B and B cells in SCID recipients at 3 weeks post-transfer. This reflected a slower kinetics of repopulation, because older NZB-->SCID recipients had numbers of both pre-B and B cells similar to recipients of young NZB progenitor cells by 10 weeks posttransplant. Adoptive transfer of equal mixtures of BALB/c and older NZB bone marrow B220- progenitor cells into irradiated C.B17 SCID recipients failed to demonstrate active suppression. These results suggest that, with age, NZB bone marrow has reduced numbers and/or function of early B220- B-lineage progenitors. Consistent with this hypothesis, B220- bone marrow cells from older NZB mice were deficient in progenitors capable of yielding interleukin-7 (IL-7) responsive pre-B cells in vitro on stimulation with the pre-B- cell potentiating factor, insulin-like growth factor 1 (IGF-1). 相似文献
34.
35.
鸟氨酸脱羧酶的生理病理特点及其药物研究概况 总被引:2,自引:0,他引:2
鸟氨酸脱羧酶(ornithinedecarboxylase,ODC)是多胺代谢中的关键酶,广泛存在于人体和动物各组织细胞内,其中对肠细胞的增生、移行和分化起重要作用.机体调节因素比较复杂.在黏膜损伤性疾病及某些癌前病变等细胞大量增生的病理情况下ODC的表达发生改变,可以作为这些疾病分期、预后及药物作用靶点或疗效的指标.寻找对ODC有作用的药物对于治疗其相关疾病是非常有意义的. 相似文献
36.
37.
ER Brown KA Charles SA Hoare RL Rye DI Jodrell RE Aird R Vora U Prabhakar M Nakada RE Corringham M DeWitte C Sturgeon D Propper FR Balkwill JF Smyth 《Annals of oncology》2008,19(7):1340-1346
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response. 相似文献
38.
39.
Bogan AM Shellhorn E Brown ES McDanald C Suppes T 《Progress in neuro-psychopharmacology & biological psychiatry》2000,24(2):351-355
1. Some reports have suggested an increase in symptoms when switching patients with psychosis from clozapine to other atypical antipsychotics. 2. No data are available on switching between atypical antipsychotics other than clozapine, though this is common in clinical practice. 3. Six patients with schizophrenia or schizoaffective disorder, bipolar type were switched to quetiapine after finishing a clinical trial of sertindole. 4. During the observation period of two to ten weeks no subjects worsened and one improved. Side effects were mild. 5. These preliminary data suggest that switching between some atypical agents may be well tolerated. Larger controlled trials are needed to confirm this observation. 相似文献
40.